Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.12, Iss.4, 2013-07, pp. : 545-557

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes

By Ahrén Bo

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 4, 2008-12 ,pp. : 593-607

Informa Healthcare

Access to resources Recommend Favorite

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences

By Baetta Roberta Corsini Alberto

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1441-1467

Adis International

Access to resources Recommend Favorite

Inhibitors of cathepsin C (dipeptidyl peptidase I)

By Laine Dramane I Busch-Petersen Jakob

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 4, 2010-04 ,pp. : 497-506

Informa Healthcare

Access to resources Recommend Favorite

Recent patents of dipeptidyl peptidase IV inhibitors

By Mendieta Laura Tarrago Teresa Giralt Ernest

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 11, 2011-11 ,pp. : 1693-1741

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

By Deacon Carolyn F Holst Jens J

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 15, 2013-10 ,pp. : 2047-2058

Informa Healthcare

Access to resources Recommend Favorite